[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"androgenetic-alopecia-aga\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:androgenetic-alopecia-aga":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,79,108,131,160,187,212,235,258,283,304,327,351],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641836","multi-omics-insights-into-androgenetic-alopecia-100641836",false,"NCT07603544","Multi-Omics Insights Into Androgenetic Alopecia","Multi-Omics Analysis of the Hair Follicle Microenvironment in Androgenetic Alopecia for Mechanistic Study and Target Identification","Inclusion Criteria:\n\n* Age and Gender: Males aged 25-30 or 60-65 years.\n* Diagnosis: Patient Group: Diagnosed by a physician with Hamilton-Norwood Stage III androgenetic alopecia (AGA). Healthy Control Group: Healthy scalp with no signs of hair loss.\n* Medication and Treatment History: No use of anti-hair loss medications (e.g., minoxidil, finasteride), hormonal drugs, or scalp chemical treatments (perm or dye) within the last 6 months.\n* Informed Consent: Voluntarily signed and provided written informed consent.\n\nExclusion Criteria:\n\n* Scalp Conditions: Presence of other types of alopecia (besides AGA) or active scalp diseases (e.g., psoriasis, dermatitis, infections).\n* Medical History: History of keloids or coagulation disorders.\n* Systemic Diseases: Major underlying conditions, including severe cardiovascular\u002Fcerebrovascular diseases, immune system disorders, or malignant tumors.\n* Allergies: Known hypersensitivity to local anesthetics.\n* Prior Clinical Trials: Participation in any other clinical trials within 3 months prior to screening.\n* Other Factors: Any other conditions deemed unsuitable for participation by the investigator.",true,"MALE","20 Years","65 Years",{"count":21,"type":22},12,"ESTIMATED","OBSERVATIONAL","This study utilizes a multi-omics approach to systematically characterize the cellular heterogeneity and spatial architecture of the hair follicle microenvironment in patients with androgenetic alopecia (AGA). Our primary aim is to elucidate the key mechanisms driving hair follicle stem cell (HFSC) exhaustion and to identify potential therapeutic targets. Investigators will collect six groups of scalp tissue samples, which include healthy controls and AGA patients (stratified into younger and older cohorts). By integrating spatial transcriptomics, single - cell sequencing data, investigators will map aberrant cell subpopulations and their complex interaction networks. Furthermore, the identified core targets will be functionally validated using patient-derived organoids and animal models. Expected outcomes include the identification of 3-5 critical cell subpopulations and the discovery of 8-10 disease-associated targets. Additionally, investigators will establish an integrated clinical-omics-validation database, providing a robust theoretical foundation for the precision diagnosis and treatment of AGA.",[26],"Androgenetic Alopecia (AGA)",[28,29],"single-cell RNA sequencing","spatial transcriptomics","RECRUITING","2026-06-11",{"date":33,"type":34},"2026-06-15","ACTUAL",{"date":36,"type":34},"2026-03-08",{"date":38,"type":22},"2027-03",{"name":40,"class":41},"The First Affiliated Hospital of Xinxiang Medical College","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":50,"minAge":51,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100617355","phase-1-study-of-abs-201-evaluating-single-and-multiple-ascending-doses-in-healthy-adults-with-and-without-androgenetic-alopecia-100617355","NCT07317544","Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia","A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Healthy Adult Participants With and Without Androgenetic Alopecia","Inclusion Criteria (Major):\n\n* Participants must be overtly healthy, as determined by medical evaluation, which includes a review of medical and surgical history, physical examination, and a 12-lead ECG.\n* Must have normal ranges for hematology, clinical chemistry, coagulation tests, and urine analysis parameters\n* Must have a body mass index (BMI) of 18 to 32 kg\u002Fm2, inclusive, at screening, with a total body weight \\>60 kg.\n* Participants, male and female, must be willing to avoid pregnancy for the duration of the trial.\n* Participants must be capable of giving signed informed consent\n* Participants must have no signs or symptoms of active or latent tuberculosis (TB),\n\nAdditional Inclusion criteria for patients with AGA:\n\n* Diagnosis of AGA with a Norwood-Hamilton Scale III vertex to V pattern.\n* Willing to clip target hair area for analysis and avoid scalp pigmentation products.\n* Willingness to maintain approximately the same hair length at each study visit\n* Additional Inclusion Criteria for postmenopausal women with AGA: Diagnosis of AGA with a Ludwig Scale I-3, I-4, II-1, II-2 pattern, with a documented history of AGA for ≥12 months and no rapid progression (e.g., sudden shedding, acute diffuse thinning, or scarring alopecia) in the 6 months prior to screening.\n\nExclusion Criteria (Major):\n\n* History or presence of cancer, except for basal cell carcinoma or cervical dysplasia successfully treated with no recurrence for ≥90 days before screening.\n* History of liver disease, Gilbert's syndrome, or abnormal liver function tests (e.g., ALT, AST, or bilirubin \\> ULN) at screening\n* Systolic blood pressure ≤90 or ≥140 mmHg, diastolic BP ≤40 or ≥90 mmHg, pulse rate \\\u003C40 or \\>100 bpm\n* Positive test for HIV, hepatitis B (HBV), or hepatitis C (HCV).\n* Recent blood donation\n* Any clinically significant psychiatric disorder\n* Pregnant or breastfeeding females or those planning pregnancy during the study.\n* History of postpartum depression, perimenopausal mood instability, or estrogen withdrawal syndrome\n\nAdditional Exclusion criteria for participants with AGA undergoing hair assessments:\n\n* Prior use of hair loss treatments:\n\n  1. Topical minoxidil within 3 months before screening.\n  2. Oral minoxidil other hair growth stimulators within 6 months before screening.\n  3. Finasteride within 6 months before screening\n  4. Dutasteride within 12 months before screening.\n* Use of GLP-1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, or similar agents) within 3 months prior to screening\n* History of hair transplantation or other major scalp procedures or planned procedures during the study.\n* Use of hair extensions, wigs, hairpieces, weaves, or any other artificial hair enhancement methods within 30 days prior to screening and throughout the study.\n* History of clinically significant dermatologic disease of the scalp that could interfere with hair assessments or target area imaging","ALL","18 Years",{"count":53,"type":22},227,"INTERVENTIONAL",[56,57],"PHASE1","PHASE2","The goal of this clinical trial is to learn if ABS-201 (a new medication) is safe and tolerable when used to improve hair growth in men and women. The trial will start with healthy volunteers and if safe, will treat participants with certain types of hair loss.\n\nThe main questions it aims to answer are:\n\nWhat medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication).\n\nParticipants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 1 year.",[26,60],"Healthy Volunteers - Male and Female",[62,63,64,65,66,67],"Androgenetic Alopecia","Hair Loss","AGA","Female hair loss","Male pattern baldness","hair regrowth","2026-05-19",{"date":70,"type":34},"2026-05-22",{"date":72,"type":34},"2025-12-03",{"date":74,"type":22},"2028-07",{"name":76,"class":77},"Absci Pty Ltd.","INDUSTRY",4,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":54,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100634162","veneze-peptide-factor-hair-serum-compared-with-topical-2-minoxidil-for-androgenetic-alopecia-100634162","NCT07536100","VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia","Effectiveness and Tolerability of VENEZE Peptide Factor Hair Serum for Pattern Hair Loss: A Randomized Double-blind Study","VENEZE-AGA","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years.\n* Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.\n* Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).\n* Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.\n* Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.\n* Able to attend all scheduled visits during the 24-week study period.\n\nExclusion Criteria:\n\n* Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).\n* History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.\n* Psychiatric disorders or other conditions that may affect participant safety or compliance.\n* Pregnant or breastfeeding women.\n\nHair and scalp-related exclusions:\n\n* Diffuse hair thinning involving the occipital area.\n* Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).\n* History of hair transplantation at any time or hair extensions within 6 months prior to screening.\n* Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.\n* Use of light\u002Flaser therapy on the scalp within 3 months prior to screening.\n* Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.\n* Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.\n* Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.\n\nMedication-related exclusions:\n\n* Known hypersensitivity to study-related products or ingredients.\n* Use of dutasteride within 12 months prior to screening.\n* Use of systemic cytotoxic agents.\n* Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).\n* Use within 6 months prior to screening of:\n\n  * Minoxidil (topical or oral)\n  * Finasteride (topical or oral)\n  * Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)\n  * Prostaglandin analogs applied to the scalp\n  * Estrogen or progesterone topical preparations\n  * Tamoxifen\n  * Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)\n  * Drugs associated with hair loss (e.g., valproic acid)\n* Participation in another clinical trial within 1 month prior to screening or during this study.",{"count":88,"type":22},80,[90],"NA","This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.",[26],[94,95,96],"Androgenetic alopecia","Peptide hair serum","Minoxidil","2026-05-09",{"date":99,"type":34},"2026-05-13",{"date":101,"type":34},"2026-05-05",{"date":103,"type":22},"2026-11-30",{"name":105,"class":106},"Institute of Dermatology, Thailand","OTHER_GOV",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":64,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":54,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":42},"100618726","phase-2-prp-combined-with-botulinum-toxin-type-a-injection-for-the-treatment-of-androgenetic-alopecia-a-study-100618726","NCT07335367","PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for AGA, confirmed by medical history, clinical presentation, and trichoscopy, with a stage of Norwood-Hamilton III to V or Ludwig I to III.\n2. Patients provide informed consent and voluntarily participate in the study.\n3. A signed informed consent form is obtained.\n4. Age between 18 and 60 years, in good general health.\n5. No use of any medications for AGA treatment within the past 6 months.\n6. Absence of alopecia areata, local infection, or neuromuscular diseases.\n\nExclusion Criteria:\n\n1. Disease duration exceeding 5 years.\n2. Patients who do not meet the diagnostic criteria for AGA.\n3. Individuals with coagulation disorders.\n4. Patients with active skin diseases or other severe systemic illnesses.\n5. Patients with blood-borne infectious diseases such as Hepatitis A, Hepatitis B, HIV\u002FAIDS, or Syphilis.\n6. Use of any medications for hair loss treatment within the past 6 months.\n7. Other conditions deemed by the investigator as unsuitable for participation, including but not limited to unreliable patients, or those unable to undergo or comprehend the study assessments.","60 Years",{"count":116,"type":22},76,[57],"Research Purpose\n\nThe objective of this study is to determine the safety and efficacy of combined PRP and BTX-A injection therapy for Androgenetic Alopecia (AGA).\n\nStudy Content\n\nThis clinical trial is a randomized (1:1), multicenter, parallel-group, controlled study. AGA patients aged 18 to 60 years presenting to the participating centers will be recruited. After providing informed consent, eligible patients who meet the inclusion\u002Fexclusion criteria will be randomized in a 1:1 ratio, with separate randomization schedules for male and female patients, into either the experimental group (PRP combined with BTX-A injection) or the control group (PRP injection only). A total of 76 patients will be enrolled.\n\nControl Group: Subjects randomized to the control group will receive PRP injection therapy. The PRP will be administered intradermally (at a depth of approximately 1.5-2.5 mm, with injection points 1 cm apart) into the scalp area (defined as ≥12 cm from the lateral canthus and ≥9 cm from the top of the ear, encompassing the frontal, temporal, parietal, and occipital regions) at a dose of 0.1 ml\u002Fcm². The treatment regimen consists of monthly injections, 4 ml per session, for a total of 3 consecutive sessions.\n\nExperimental Group: Subjects randomized to the experimental group will receive injections using the same method and frequency as the control group. For the first session, the injection will consist of 100U of BTX-A reconstituted in 4 ml of PRP. The second and third sessions will be identical to those in the control group (PRP injection only).\n\nFollow-up Assessments: For all subjects, a safety evaluation will be conducted 14 days after the first treatment, along with scalp care guidance provided by the investigator. Subsequent safety and efficacy assessments will be performed at 1, 2, 3, and 6 months following the initial treatment.",[26],[121],"Platelet-Rich Plasma","2026-04-13",{"date":124,"type":34},"2026-04-14",{"date":126,"type":34},"2026-01-09",{"date":128,"type":22},"2026-08-31",{"name":130,"class":41},"Nanfang Hospital, Southern Medical University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":54,"phases":141,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":42},"100632796","phase-4-the-effect-of-nanofat-injection-on-androgenetic-alopecia-100632796","NCT07518342","The Effect of Nanofat Injection on Androgenetic Alopecia","Efficacy and Safety of Nanofat Injection vs Either PRP Injection or Topical Minoxidil 5% in Female and Male Pattern Androgenetic Alopecia","Inclusion criteria:\n\n* Adults (ages 18-50).\n* A clinical diagnosis of androgenetic alopecia confirmed by dermoscopy of both males and females.\n* No previous topical treatment used in the past 3 months.\n\nExclusion criteria:\n\n* Alopecia totalis and alopecia universalis.\n* Cicatricial alopecia.\n* Other causes of hair loss such as immunological disease.\n* Skin disease in the affected area.\n* Hypersensitivity or allergy to any of the treatment products used.\n* Patients using treatment (topical or systemic) for androgenetic alopecia in the last 3 months.\n* Pregnant and lactating females.\n* Patients with a history of hypertrophic scars or keloid formation.\n* Patients with active infection at the site of the lesion.\n* Skin disease in the affected area.\n* Hamilton norwood scale stage 6 and 7\n* Ludwig Scale stage 3","50 Years",{"count":140,"type":22},60,[142],"PHASE4","Androgenetic alopecia is a condition that bothers a lot of people. The disadvantage of the FDA approved topical minoxidil is that the patient needs to be compliant every day for extended periods of time. This is the main reason why this study is being conducted, to see if a single nanofat injection is superior to applying either topical Minoxidil or PRP",[62,26],[62,146,147,148,149,96,150],"Alopecia","PRP","nanofat","nanofat injection","Topical minoxidil","NOT_YET_RECRUITING","2026-04-08",{"date":122,"type":34},{"date":155,"type":22},"2026-04",{"date":157,"type":22},"2028-12",{"name":159,"class":41},"Assiut University",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":114,"enrollmentInfo":168,"targetDuration":4,"studyType":54,"phases":170,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100633691","phase-3-phase-3-study-to-evaluate-the-efficacy-and-safety-of-oral-minoxidil-n1087-in-men-with-androgenetic-alopecia-100633691","NCT07529977","Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.","A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Male Participants With Androgenetic Alopecia.","MINORA-MEN","Inclusion Criteria:\n\n* Male participants aged 18 to 60 years at the time of signing the informed consent form.\n* Clinical diagnosis of androgenetic alopecia classified as stages 3V, 4, or 5 according to the Norwood-Hamilton scale, based on the investigator's clinical assessment.\n* No specific treatment for androgenetic alopecia in the last 6 months, or history of specific treatment for androgenetic alopecia for up to 30 days within the last 6 months.\n* Willingness to comply with all study procedures and assessments, including permanent scalp tattooing and shaving of the target area.\n* Willingness to maintain hairstyle, hair length, and hair color throughout the study.\n* Willingness to maintain consistent use of hair products and general hair care routine throughout the study.\n* Global scalp photograph obtained at Screening Visit validated centrally prior to randomization.\n\nExclusion Criteria:\n\n* Presence of other causes of alopecia, such as alopecia areata, scarring alopecia, traction alopecia, nutritional deficiency-related alopecia, monilethrix, trichotillomania, trichodystrophy, or chemotherapy-induced alopecia.\n* History of telogen effluvium within the last 6 months.\n* Presence of other dermatological conditions affecting the scalp, such as seborrheic dermatitis, psoriasis, eczema, or fungal infections.\n* Clinically relevant uncontrolled endocrine disorders that may affect the hair cycle.\n* Uncontrolled thyroid disease.\n* History of autoimmune diseases or collagen vascular diseases.\n* Use of testosterone, its analogues, anabolic steroids, or other systemic androgen therapies within the last 6 months.\n* History of organ transplantation.\n* Physical treatments for hair loss within the last 6 months, such as microneedling, laser therapy, or platelet-rich plasma.\n* History of hair transplantation or use of hairpieces.\n* Severe uncontrolled systemic arterial hypertension or hypotension.\n* History of significant cardiovascular disease, including myocardial infarction, unstable angina, or congestive heart failure (NYHA class III or IV).\n* History or suspicion of pulmonary hypertension associated with mitral stenosis or pheochromocytoma.\n* History of peripheral edema, lymphedema, ascites, or pericardial effusion.\n* Resting tachycardia (heart rate ≥100 bpm).\n* Moderate to severe renal, hepatic, or cardiovascular disease.\n* History of malignancy within the last 5 years, except for successfully treated non-metastatic basal or squamous cell carcinoma of the skin.\n* Current use of potent vasodilators or other prohibited medications.\n* Known allergy or hypersensitivity to minoxidil or any component of the formulation.\n* Hairstyles that may interfere with study assessments, such as permanent braids or dreadlocks.\n* Participants with reproductive potential whose partner does not agree to use effective contraception during the study.\n* Participation in another clinical trial within the last 12 months.\n* Clinically significant laboratory abnormalities at randomization, including HbA1c ≥8%, estimated glomerular filtration rate \\\u003C45 mL\u002Fmin, elevated liver enzymes (\\>2× ULN), abnormal thyroid-stimulating hormone levels, clinically significant ECG abnormalities, hemoglobin \\\u003C13 g\u002FdL, or hematocrit \\\u003C39%.",{"count":169,"type":22},372,[171],"PHASE3","This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).\n\nThe study will include male participants aged 18 to 60 years who have a clinical diagnosis of androgenetic alopecia classified as stages 3V, 4, or 5 on the Norwood-Hamilton scale. Participants will be randomly assigned, in a 2:1 ratio, to receive either N1087 or placebo. Neither the participants nor the study team will know which treatment each participant receives.\n\nThe study treatment will be taken orally once daily for a total of 24 weeks. During the first 8 weeks, the dose will be gradually increased (titration period) up to a maximum tolerated dose, not exceeding 5 mg. Participants will then continue treatment at the maximum tolerated dose for the remaining 16 weeks.\n\nThe main purpose of the study is to assess whether oral minoxidil improves hair growth. The primary outcome measure is the change from baseline in the density of non-vellus hairs in a defined target area of the scalp (vertex) after 24 weeks of treatment, measured using digital phototrichogram analysis.\n\nSecondary objectives include evaluating changes in hair density at earlier time points, hair thickness, the proportion of terminal hairs, clinical improvement assessed by the investigator, quality of life related to hair loss, and participant satisfaction with treatment.\n\nThe safety and tolerability of oral minoxidil will also be evaluated by monitoring adverse events, vital signs, and events of special interest throughout the study. An independent Data and Safety Monitoring Committee will oversee participant safety during the trial.\n\nThis is a multicenter study conducted in Brazil, with approximately 372 participants expected to be enrolled.",[62,26],[94,175,176,177,178,179],"Male pattern hair loss","N1087","Hair growth","Phototrichogram","Phase 3 clinical trial",{"date":124,"type":34},{"date":182,"type":22},"2027-01-31",{"date":184,"type":22},"2028-10-30",{"name":186,"class":77},"Eurofarma Laboratorios S.A.",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":54,"phases":195,"briefSummary":196,"conditions":197,"keywords":202,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100565951","phase-2-clinical-study-of-da-001-as-a-treatment-for-hair-shedding-reduction-and-hair-re-growth-100565951","NCT06648850","Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with telogen effluvium\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-001\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits",{"count":194,"type":22},1120,[57,171],"The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth",[198,199,200,201,62,26],"Telogen Effluvium","Female Pattern Hair Loss","Female Pattern Hair Loss, Androgenic Alopecia","Male Pattern Baldness",[203,204],"Hair Shedding","hair growth",{"date":122,"type":34},{"date":207,"type":22},"2026-05-01",{"date":209,"type":22},"2027-04-26",{"name":211,"class":77},"Applied Biology, Inc.",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":114,"enrollmentInfo":219,"targetDuration":4,"studyType":54,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":42},"100621430","phase-2-topical-application-of-lactobacillus-reuteri-for-androgenetic-alopecia-100621430","NCT07370519","Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia","Safety and Efficacy of Lactobacillus Reuteri for Androgenetic Alopecia: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Patients meeting AGA diagnostic criteria (confirmed by medical history, clinical presentation, and trichoscopy) classified as Norwood-Hamilton stage II-IV or Ludwig grade I-III;\n2. Provision of informed consent and voluntary participation;\n3. Aged 18-60 years with generally good health status;\n4. No use of any hair loss medications within the past six months;\n5. Absence of alopecia areata, local infections, or neuromuscular disorders.\n\nExclusion Criteria:\n\n1. AGA progression \\>5 years;\n2. Active skin disease (e.g., psoriasis flare) or uncontrolled diabetes\u002FCVD;\n3. Investigator-assessed protocol non-feasibility.",{"count":220,"type":22},388,[57],"This is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate whether topical application of Lactobacillus reuteri can safely and effectively treat androgenetic alopecia. The study is based on the concept that balancing the scalp's microbial community may support hair follicle function. Participants will be randomly assigned to one of four groups receiving either active probiotic solution, inactivated probiotic solution (control for non-viable bacterial effects), a saline placebo, or the standard treatment 5% minoxidil solution for 12 months. Neither participants nor assessing clinicians will know the assigned treatment. The main goal is to measure improvement in hair count per square centimeter after one year. Additional measures include changes in hair thickness and quality. This research seeks to provide high-quality scientific evidence on a new microbiome-targeting approach, offering future patients and healthcare providers insights into a potential alternative or complementary treatment strategy for hair loss.",[26],[62,225],"Lactobacillus reuteri","2026-03-31",{"date":228,"type":34},"2026-04-01",{"date":230,"type":34},"2026-01-25",{"date":232,"type":22},"2027-06",{"name":234,"class":41},"Shenzhen People's Hospital",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":54,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":42},"100618110","phase-1-a-study-to-evaluate-safety-and-efficacy-of-olx72021-in-healthy-males-with-androgenetic-alopecia-100618110","NCT07327359","A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1b\u002F2a Study to Evaluate the Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia","Inclusion Criteria:\n\n* Adult male.\n* 18 to 59 years.\n* Androgenetic Alopecia (Hamilton-Norwood III-V).\n* Body mass index (BMI) ≥ 18.0 kg\u002Fm2, with a body weight ≥ 50 kg at screening.\n* Non-smoker.\n* Medically healthy without clinically significant abnormalities.\n* Willing and able to tolerate multiple injections and attend all study visits.\n* Willing to have blood drawn.\n\nExclusion Criteria:\n\n* History or presence of significant pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically significant.\n* Uncontrolled diabetes mellitus.\n* Immunodeficiency disorders.\n* History of clinically significant heart disease.\n* History of risk factors for torsade de pointes.\n* Any dermatological disorders of the scalp.\n* History or clinical signs of keloids or hypertrophic scars.\n* History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen effluvium, or conditions other than AGA.\n* History of surgical correction of hair loss or hair transplant on the scalp.\n* History of radiation of the scalp at any time.\n* Use of semi-permanent hair products.\n* Use of an occlusive wig, hair extensions, or hair weaves for the duration of the study.\n* Use of cosmeceuticals or over-the-counter (OTC) hair regrowth products \\\u003C 2 weeks prior to the first dose of study drug.\n* Use of topical\u002Flocal treatments.\n* Use of non-topical\u002Flocal medications within 24 weeks prior to the first dose of study drug\n* Anti-cancer agents, including cytotoxic agents, that can potentially have effects on alopecia within 12 months prior to the first dose of study drug\n* Scalp hair loss on the treatment area due to disease, injury, or medical therapy.\n* Current infection that requires systemically absorbed or topical antibiotic, antifungal, antiparasitic, or antiviral medications.\n* Any history of malignant disease in the last 5 years (excludes surgically resected skin squamous cell or basal cell carcinoma).\n* Positive test results for active human immunodeficiency virus-1 or 2 (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.\n* Positive drugs of abuse test, alcohol breath test, or cotinine test at the screening visit and prior to the first administration of study treatment.\n* Use of any vaccinations within 14 days prior to the first study drug administration.\n* Donation of blood or plasma within 30 days prior to first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to first study drug administration, or receipt of a blood transfusion within 1 year of first study drug administration.\n* Treatment with an investigational drug in another clinical trial within 60 days or 5 half lives of the other investigational drug (whichever is longer) prior to the first administration of study drug in this trial.\n* Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.\n* Known hypersensitivity to the study drug or any of the study drug ingredients.\n* History of surgery or hospitalization within 3 months prior to screening, or surgery planned during the study.\n* Regular consumption of more than 10 standard alcoholic drinks\u002Fweek and\u002For more than 2 standard alcoholic drinks on any one day.\n* Refusal to provide informed consent.","59 Years",{"count":244,"type":22},158,[56,57],"This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.",[26],[249],"Male Pattern Hair Loss","2026-03-04",{"date":252,"type":34},"2026-03-06",{"date":254,"type":34},"2025-12-04",{"date":38,"type":22},{"name":257,"class":77},"Olix Pharmaceuticals, Inc.",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":265,"minAge":51,"maxAge":19,"enrollmentInfo":266,"targetDuration":4,"studyType":54,"phases":268,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":282},"100604169","phase-3-safety-and-efficacy-of-vdphl01-in-females-with-androgenetic-alopecia-aga-100604169","NCT07146022","Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia","Inclusion Criteria:\n\n* Subject is a female aged 18-65 years old;\n* Subject has a clinical diagnosis of mild to moderate AGA;\n* Subject is in good general health and has adequate renal and hepatic function;\n* Subject is willing to maintain at least 1\u002F4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;\n* Subject is willing and able to administer the test article as directed and can read, understand, and complete the required questionnaires in English;\n* Subject is willing and able to swallow study drug whole;\n* Subject agrees to have a micro dot tattoo placed on their scalp;\n* Subject agrees to have this area photographed at study visits as indicated in the protocol.\n\nExclusion Criteria:\n\n* Subject has uncontrolled blood pressure or orthostatic hypotension;\n* Subject has symptoms or history of certain heart or thyroid conditions;\n* Subject has a history of or active hair loss due to conditions\u002Fdiseases other than AGA;\n* Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists;\n* Subject has been diagnosed with COVID-19 within 16 weeks of baseline;\n* Subject has had previous radiation of the scalp;\n* Use of any of the following treatments within the indicated washout period before screening:\n\n  * Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening\n  * Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening\n  * Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening\n  * Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening\n  * Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, platelet rich plasma within 6 months prior to screening\n  * Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening\n  * Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study;\n  * Subject has any other condition that, in the investigator's opinion, interfere with the study","FEMALE",{"count":267,"type":22},552,[171],"This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA).\n\nAGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.\n\nThis multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).",[26,62,64,271,63],"Female Androgenetic Alopecia",[62,64,63],"2025-11-18",{"date":275,"type":34},"2025-11-24",{"date":277,"type":34},"2025-07-25",{"date":279,"type":22},"2028-01",{"name":281,"class":77},"Veradermics, Inc.",71,{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":54,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":42},"100599066","thulium-laser-and-growth-factors-for-androgenetic-alopecia-100599066","NCT07079657","Thulium Laser and Growth Factors for Androgenetic Alopecia","Thulium Laser and Growth Factors for Androgenetic Alopecia - a Prospective, Clinical Study","Inclusion Criteria:\n\n* Men and women aged 18 and over\n* Good general health, no relevant previous illnesses\n* Presence of an AGA\n* Cognitive ability and willingness to give consent (informed consent)\n* Be willing and able to attend follow-up visits\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant or breastfeeding women\n* Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs\n* Significant scarring of the region to be treated\n* Significant open wounds or lesions in the region to be treated\n* Metallic implants in the head region\n* Mental illnesses (psychoses, body perception disorders)\n* Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks\n* Resurfacing (fractional, ablative, non-ablative) of the affected region \\\u003C 2 months before and during the study period\n* Tendency to excessive scarring\n* Lack of informed consent and\u002For data protection declarations",{"count":291,"type":22},30,[90],"Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected.\n\nVarious therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity.\n\nDespite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.",[26],"2025-07-21",{"date":297,"type":34},"2025-07-23",{"date":299,"type":34},"2023-12-01",{"date":301,"type":22},"2025-10-01",{"name":303,"class":41},"Universitätsklinikum Hamburg-Eppendorf",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":19,"enrollmentInfo":310,"targetDuration":4,"studyType":54,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":42},"100594354","low-dose-oral-minoxdil-in-androgenic-alopecia-100594354","NCT07018349","Low Dose Oral Minoxdil in Androgenic Alopecia","Inclusion Criteria:\n\n* Patients have a clinical and trichoscopic diagnosis of mild to severe AGA\n\nExclusion Criteria:\n\n* Patients who, within three months before the trial, had undergone systemic or topical therapies for AGA\n* People who suffer from additional hair loss conditions such hyperandrogenism, scarring or inflammatory alopecia, or any hormonal disorders.\n* Sensitivity to minoxidil\n* Patients with history of severe systemic diseases (heart, renal, or hepatic), a history of hypertension or hypotension, pregnant and breast-feeding women will also be excluded.\n* Patient who will not be willing to provide written informed consents.",{"count":116,"type":22},[90],"In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg. It addresses a critical gap in current research, as few studies have examined the relationship between low dosage and outcomes like hair diameter, density, patient satisfaction, and adverse effects, including hypertrichosis. Previous research suggests that low dose of oral minoxidil is a safe and well-tolerated option for hair loss, but the optimal dose for maximizing benefits while minimizing side effects remains unclear. This study aims to determine which dose offers the best balance of efficacy and safety for AGA patients.",[26],[315,316,317],"androgenetic alopecia (AGA)","Minoxdil","Low oral doses","2025-06-10",{"date":320,"type":34},"2025-06-12",{"date":322,"type":22},"2025-06-15",{"date":324,"type":22},"2025-10-20",{"name":326,"class":106},"Jinnah Postgraduate Medical Centre",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":265,"minAge":51,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":54,"phases":336,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":42},"100593903","early-phase-1-efficacy-of-dihydroartemisinin-for-treating-female-androgenetic-alopecia-100593903","NCT07012486","Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia","A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Female Androgenetic Alopecia","Inclusion Criteria:\n\n* Clinically diagnosed with androgenetic alopecia (AGA)\n* No pregnancy plans within the next 6 months\n\nExclusion Criteria:\n\n* Patients who received systemic medications for hair loss within the past 2 months\n* Use of topical medication for hair loss within the past 2 weeks\n* Pregnancy or lactation\n* Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.","40 Years",{"count":291,"type":22},[337],"EARLY_PHASE1","The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:\n\n• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.\n\nParticipants will:\n\n* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months.\n* Visit the clinic once every month for checkups and tests.",[26],[341,342],"androgenetic alopecia","dihydroartemisinin","2025-06-09",{"date":318,"type":34},{"date":346,"type":22},"2025-06",{"date":348,"type":22},"2026-12",{"name":350,"class":41},"Shanghai Zhongshan Hospital",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":54,"phases":361,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":42},"100563950","phase-2-to-evaluate-efficacy-and-safety-of-topicalkx-826-solution-in-chinese-male-patients-with-androgenetic-alopecia-100563950","NCT06622824","To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia","Efficacy and Safety of Topical KX-826 Solution in Chinese Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-blind, Vehicle Controlled Adaptive Design Phase 2\u002F3 Study","Inclusion Criteria:\n\n1. Agree to comply with study procedures and visit plan. Subject is capable of giving informed consent;\n2. Male between the ages of 18 and 49 years, inclusive;\n3. Clinically diagnosed as androgenetic alopecia;\n4. Rating IIIv, IV and V on the Norwood Hamilton Scale; subject is willing to receive a ink dot tattoo;\n5. Subject is willing to maintain the same hairstyle, hair length, and hair color at each visit;\n6. Willing to use highly effective contraceptive measures during the study period and 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Had a history or active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania, or conditions\u002Fdiseases other than AGA;\n2. Had gray hair in the target alopecia area;\n3. Had too short hair that, in the investogator's opinion, might affect hair growth assessment;\n4. Had any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the investigational drug (e.g., fungal or bacterial infection, severe seborrheic dermatitis, solar keratosis, scalp psoriasis, contact dermatitis, severe folliculitis or scalp atrophy);\n5. Had a significant increase in hair loss determined by investigator within 6 months prior to screening;\n6. Had scalp hair transplants or hair extension history; need of wearing wig for a long time during the study;\n7. Subjects who plan to use any adjuvant or concomitant therapy for the treatment of alopecia throughout the study;\n8. Subjects with a previous or current diagnosis of hyperthyroidism or hypothyroidism;\n9. Subjects with diseases that affect hair growth, such as connective tissue disease, inflammatory bowel disease, moderate to severe anemia, and significant short-term weight loss;\n10. Had used finasteride or dutasteride prior to screening;\n11. Had used platelet rich plasma (PRP) procedure within 12 months prior to screening;\n12. Had used scalp surgical procedure within 12 months prior to screening; Had used laser, light, or energy treatments within 6 months of screening;\n13. Had used anti-androgenic drugs (e.g., flutamide, cyproterone, drospirosterone, estrogen, progesterone, cimetidine, spironolactone, or oral ketoconazole, etc) within 6 months prior to screening;\n14. Had used the following medications that may affect the evaluation of efficacy in the study within 6 months prior to screening:\n\n    * Oral or topical minoxidil\n    * Systemic interferon\n    * Immunosuppressants such as cyclosporine\n    * Diuretics\n    * Beta-blockers (e.g., propranolol, atenolol, metoprolol, etc)\n    * Anticoagulants (e.g., warfarin, heparin, heparin analogues, etc)\n    * Anti-thyroid drugs (e.g., thiouracil, methiimidazole, etc)\n    * Antipsychotic drugs (e.g., valproic acid, carbamazepine, phenytoin sodium, phenothiazines, fluoxetine, etc)\n    * Anti-retroviral drugs (e.g., zidovudine, indonavir, ritonavir, lopinavir, etc)\n    * Retinoids (e.g., actinoic acid, isotretinoic acid, etc), or use vitamin A supplements or A daily dietary intake of more than 10,000 IU of vitamin A\n15. Used systemic steroids for more than 14 consecutive days within 3 months prior to screening;\n16. Used oral hair growth supplements or herbs within 3 months prior to screening;\n17. Use of hair growth shampoo such as ketoconazole or solution within 1 month prior to screening;\n18. Subjects with acute infection of novel coronavirus and receiving (attenuated) live vaccine within 1 month prior to screening;\n19. Abnormal and clinically significant findings in physical examination, vital signs, 12-lead ECG, hematology, urinalysis, blood chemistry, and thyroid function test at screening, which will affect the efficacy and safety evaluation and study results as judged by the investigator;\n20. Positive blood screen for human immunodeficiency virus(HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or treponema pallidum antibody;\n21. Have treated with KX-826 or GT20029 previously;\n22. Subjects with sleep disorders, as assessed by the investigator, that affect hair growth, or the efficacy evaluation;\n23. Subjects with depression, anxiety, or personality disorders, as assessed by the investigator, that affect hair growth, or the efficacy evaluation;\n24. Has a known hypersensitivity or previous allergic reaction to any of the active or inactive ingredients in the investigational drug;\n25. Medical\u002Fsurgical history of any uncontrolled systemic disease that is serious or may affect the safety and efficacy evaluation of the investigational product, such as cardiovascular system, nervous system, hematological system, immune system, and psychiatric system disease;\n26. Have undergone major surgery within 6 months prior to screening, or plan to undergo major surgery during the study;\n27. Had a history of malignancy (except for cured carcinoma in situ) within 5 years prior to screening;\n28. Subjects who have participated or are participating clinical studies of interventional drugs or medical devices within 3 months prior to screening;\n29. Had a history of drug abuse within 12 months prior to screening;\n30. Subjects who consumed large amounts of tea\u002Fcoffee within 3 months prior to screening, as assessed by the investigator, that may affect hair growth, or the efficacy evaluation;\n31. Subjects who, in the opinion of the investigator, have other conditions that may affect compliance or are not suitable for participation in this study;","49 Years",{"count":360,"type":22},756,[57,171],"This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2\u002F3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA). It consisted of two phases, phase 2 dose exploration trial and phase 3 confirmatory trial.",[26],[341,365],"Hair loss","2024-10-17",{"date":368,"type":34},"2024-10-21",{"date":370,"type":22},"2024-10-15",{"date":372,"type":22},"2028-06-30",{"name":374,"class":77},"Suzhou Kintor Pharmaceutical Inc,"]